STM JOURNALS

International Journal of
Virus Studies

Volume 1, Issue 2, 2024
July–December
DOI (Journal): 10.37591/IJVS

https://journals.stmjournals.com/ijvs/

Review IJBS

Development of a Novel Therapeutic Approach Using RNA Interference for Targeting Viral Genes

Safiya Sajid*

Abstract

RNA interference (RNAi) is a groundbreaking therapeutic strategy that holds immense promise for targeting viral genes in the treatment of viral infections. This approach leverages the natural gene-silencing mechanisms of RNAi to inhibit viral replication and expression at the molecular level, providing a precise and adaptable method to counteract viral pathogens, including influenza, HIV, and hepatitis viruses. Recent advancements in RNAi technology have enabled the development of highly specific small interfering RNAs (siRNAs) and microRNAs (miRNAs) that can selectively target and degrade viral mRNA, impeding the virus's life cycle. However, challenges in effective delivery, off-target effects, and immune response activation remain barriers to clinical implementation. This review examines the molecular mechanisms underlying RNAi, explores current advancements in RNAi delivery systems, and evaluates its therapeutic potential and limitations as an antiviral approach. Additionally, we highlight the future directions of RNAi, emphasizing the integration with complementary therapies, such as CRISPR gene editing, to enhance its efficacy and applicability in treating viral infections.

Keywords: RNA interference (RNAi)**,** antiviral therapy**,** viral gene targeting**,** small interfering RNA (siRNA), microRNA (miRNA)**,** gene silencing**,** RNAi delivery systems**,** viral infections**,** CRISPR/Cas9**,** immunogenicity

INTRODUCTION

Viral infections remain a significant global health challenge, affecting millions of individuals and leading to high morbidity and mortality rates. Traditional antiviral therapies have limitations, including narrow-spectrum efficacy, the emergence of viral resistance, and potential toxicity [1]. For example, existing drugs like acyclovir for herpes viruses and oseltamivir for influenza demonstrate varying effectiveness, primarily due to resistance mechanisms developed by the viruses. This situation underscores the urgent need for innovative therapeutic strategies that can effectively target and inhibit viral replication [2].

Overview of Viral Infections

Viral pathogens, including Human Immunodeficiency Virus (HIV), Influenza Virus, Hepatitis C Virus (HCV), and more recently, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), pose substantial public health threats [1]. According to the World Health Organization (WHO), viral hepatitis alone claims approximately 1.34 million lives annually, while HIV/AIDS remains a leading cause of death in many parts of the world shown in Table 1 [3].

***Author for Correspondence**
Safiya Sajid
E–mail: safiya.sajid28@gmail.com

Student, Department of Pharmacy, Prasad Institute of Technology, Jaunpur, Uttar Pradesh, India.

Received Date: October 27, 2024
Accepted Date: October 29, 2024
Published Date: November 12, 2024

Citation: Safiya Sajid. Development of a Novel Therapeutic Approach Using RNA Interference for Targeting Viral Genes. International Journal of Virus Studies. 2024; 1(2): 12–22p.

Limitations of Current Antiviral Therapies

The traditional approaches to antiviral therapy predominantly focus on inhibiting viral enzymes or proteins. However, these treatments often lead to rapid viral mutation and resistance, significantly diminishing their long-term effectiveness [1]. For

instance, the emergence of oseltamivir-resistant strains of the influenza virus illustrates the challenge of maintaining efficacy against rapidly evolving pathogens. Additionally, some antiviral drugs can induce adverse side effects, complicating patient management [4].

Introduction to RNA Interference

One natural biological mechanism that regulates gene expression and is used for therapeutic purposes is RNA interference (RNAi) [5]. By binding to complementary messenger RNA (mRNA) sequences, small interfering RNAs (siRNAs) and microRNAs (miRNAs) cause translational repression or mRNA destruction, which is how RNA interference (RNAi) works. Mechanism of RNA interference are shown in Figure 1. This technique offers a potent method of mutating viral genes, which prevents the virus from replicating and spreading [4].

Table 1. Global burden of major viral infections.

Viral Infection	Annual Cases (Approx.)	Annual Deaths (Approx.)
HIV/AIDS.	38 million.	1.2 million.
Influenza.	1 billion.	290,000–650,000.
Hepatitis B.	257 million.	887,000.
Hepatitis C.	71 million.	400,000.
COVID-19.	600 million (cumulative).	6.9 million (cumulative).

Source: WHO.



Figure 1. Mechanism of RNA interference.

Historical Context and Evolution of RNAi in Therapeutics

The discovery of RNAi can be traced back to the early 1990s, with the first reports emerging from studies in Caenorhabditis elegans. The subsequent realization of RNAi's potential in mammalian cells marked a pivotal shift in molecular biology, with researchers recognizing its implications for therapeutic applications [2]. Over the past two decades, extensive research has been conducted to develop RNAi-based therapeutics targeting various diseases, including cancer and genetic disorders.

RNAi therapeutics that target viral infections have been made possible by recent scientific advancements. Clinical trials are underway to assess the efficacy of siRNAs against viral genes in pathogens, such as HIV, HCV, and SARS-CoV-2. These promising developments indicate a significant step towards harnessing RNAi as a viable antiviral strategy [6].

Significance of RNAi in Antiviral Drug Development

RNAi-based treatments have several benefits over conventional antiviral methods. First, they have the potential for high specificity, allowing for the targeted silencing of viral genes without affecting host genes. Second, RNAi can be designed to target conserved regions of viral genomes, potentially

reducing the likelihood of resistance development. Finally, the modular nature of RNAi enables rapid adaptation to target emerging viral strains [5].

MECHANISM OF RNA INTERFERENCE

RNA molecules efficiently silence certain genes by preventing gene expression or translation through a biological process known as RNA interference (RNAi) [7]. This section explores the molecular mechanisms underlying RNAi, detailing how it functions, the components involved, and its implications for antiviral therapies [7].

Molecular Components of RNA Interference

The RNA-induced silencing complex (RISC), the target messenger RNA (mRNA), and small interfering RNAs (siRNAs) are the three main elements of the RNAi pathway [8].

Small Interfering RNAs (siRNAs)

The lengthy double-stranded RNA (dsRNA) molecules that give rise to siRNAs are usually 21–23 nucleotides long. [These dsRNAs can be introduced into cells through various methods, such as transfection or viral vectors, or can be produced endogenously in response to viral infections [6].

Dicer Enzyme

The enzyme Dicer plays a crucial role in the RNAi pathway by processing long dsRNA into siRNAs. Dicer recognizes the dsRNA, cleaving it into short, functional siRNA molecules that are then loaded onto the RISC [7].

RNA-Induced Silencing Complex (RISC)

The RISC is a multi-protein complex responsible for the gene silencing function of siRNAs. Once loaded with an siRNA, RISC is guided to its complementary target mRNA. The key proteins in RISC include Argonaute (Ago), which is essential for mRNA cleavage and degradation [4].

Target mRNA

The mRNA that is complementary to the siRNA sequence becomes the target of the RISC. When RISC binds to the mRNA, it leads to the silencing of gene expression [2].

Mechanism of Action

The action of RNAi can be summarized in the following steps:

- *Introduction of dsRNA:* The process begins with the introduction of dsRNA into the cell, either through transfection or viral infection.
- *Processing by Dicer:* The dsRNA is converted to siRNAs by Dicer. The two strands that make up each siRNA are the passenger strand, which is typically destroyed, and the guide strand, which is complementary to the target mRNA.
- *Loading onto RISC:* The siRNA's passenger strand is thrown away, while the guide strand is integrated into the RISC.
- *Target recognition:* RISC, now armed with the guide strand, binds to complementary mRNA sequences through base-pairing interactions.
- *mRNA cleavage:* The Ago protein within RISC possesses endonuclease activity, leading to cleavage of the target mRNA. This cleavage usually occurs in the middle of the mRNA molecule, rendering it non-functional.
- *Degradation of cleaved mRNA:* The cleaved mRNA fragments are subsequently degraded by cellular exonucleases, preventing translation and leading to reduced protein synthesis [8].

TYPES OF RNA INTERFERENCE

- *Natural RNA interference:* Naturally occurring RNAi mechanisms exist in many organisms and play a vital role in gene regulation, defence against viruses, and maintenance of genomic stability.

- *Artificial RNA interference:* This refers to the laboratory-induced RNAi, achieved through the introduction of synthetic siRNAs or shRNAs (short hairpin RNAs) designed to target specific mRNA sequences for silencing.
- *Viral RNA interference:* Some viruses have developed mechanisms to counteract RNAi, but they can also be targeted by engineered RNAi approaching to enhance antiviral responses [6, 7, 9].
- *Implications for antiviral therapies:* The ability of RNAi to specifically target and silence viral genes presents a transformative approach in antiviral drug development. By targeting conserved regions of viral genomes, RNAi can overcome challenges posed by viral mutation and resistance. For instance, siRNAs can be designed to target critical viral proteins involved in replication, thereby inhibiting viral propagation [4].

Key Advantages of RNAi in Antiviral Applications

- *Specificity:* RNAi allows for high specificity in targeting viral genes, reducing off-target effects.
- *Reduced resistance:* By targeting multiple viral genes or conserved regions, the development of resistant viral strains may be minimized.
- *Broad applicability:* RNAi can be adapted to target a wide range of viruses, including those lacking effective treatments [8].

Design and Synthesis of siRNAs

The successful application of RNA interference (RNAi) in antiviral therapy largely hinges on the effective design and synthesis of small interfering RNAs (siRNAs). This section elaborates on the methodologies for siRNA design, considerations for synthesis, and factors influencing the efficacy of siRNAs in silencing targeted viral genes [5].

Principles of siRNA Design

When designing siRNAs, several key principles must be followed to ensure optimal functionality;

- *Target selection:* The first step in siRNA design is identifying a suitable target sequence within the viral genome. The target region should be highly conserved across different viral strains to avoid resistance development. Sequences coding for essential viral proteins, such as those involved in replication, are often selected.
- *Length and structure:* Effective siRNAs are typically 21–23 nucleotides in length, with two nucleotides overhanging at the 3’ ends. This structure improves stability and makes integration into the RNA-induced silencing complex (RISC) easier.
- *GC content:* An optimal GC content (40-60%) in the siRNA sequence is crucial for maintaining stability and reducing off-target effects. Increased immunogenicity may result from a high GC concentration, which can also improve thermodynamic stability.
- *Strand selection:* The two strands that make up siRNAs are the passenger strand and the guide strand. The guide strand complements the target mRNA, whereas the passenger strand usually undergoes degradation.

  Careful selection of the guide strand is critical for target specificity.
- *Avoiding unwanted targeting:* The design process should incorporate algorithms to predict potential off-target effects, where the siRNA might bind to unintended mRNA sequences. Tools, such as BLAST and specialized software (e.g., siRNA Design Tool) can assist in identifying potential off-target sites [4].

Synthesis of siRNAs

The synthesis of siRNAs can be achieved through several methodologies:

- *Chemical synthesis:* This is the most common method for producing siRNAs. Solid-phase synthesis of RNA oligonucleotides enables the assembly of siRNAs with precise nucleotide sequences. Chemical modifications, such as phosphorothioate linkages or 2’-O-methylation, can enhance stability and reduce immunogenicity.

- *In vitro transcription:* siRNAs can also be produced via in-vitro transcription of DNA templates using bacteriophage polymerases. This approach allows for the generation of long double-stranded RNA (dsRNA) that can then be processed into siRNAs by Dicer.
- *Synthetic libraries:* The creation of libraries of siRNAs allows for high-throughput screening of multiple sequences to identify the most effective candidates against specific viral targets. This can involve automated synthesis platforms [10].

Factors Influencing siRNA Efficacy

Several factors can impact the efficacy of siRNAs in silencing target genes and comparison of siRNA synthesis methods are shown in Table 2.

Delivery Efficiency

The efficacy of siRNAs depends on their capacity to infiltrate target cells. Delivery methods, including liposomes, nanoparticles, and viral vectors, play a significant role in achieving successful transfection.

Cellular Uptake

The uptake of siRNAs can be influenced by cell type, receptor-mediated endocytosis, and the presence of competing nucleases that degrade RNA molecules.

Stability in Biological Environments

The stability of siRNAs in serum and other biological fluids is essential for therapeutic applications. Modifications to the siRNA structure can enhance resistance to degradation.

Immunogenicity

siRNAs can elicit immune responses, which may diminish their therapeutic potential. Designing siRNAs that minimize recognition by pattern recognition receptors (PRRs) can help reduce unwanted immune activation [11].

Table 2. Comparison of siRNA synthesis methods.

Method	Advantages	Disadvantages
Chemical synthesis.	High purity, precise control over sequence.	Expensive, requires specialized equipment.
In vitro transcription.	Scalable, can produce long dsRNA.	Less control over product quality.
Synthetic libraries.	High-throughput screening of multiple candidates.	Initial setup can be time-consuming.

DELIVERY METHODS FOR RNAI THERAPEUTICS

The therapeutic potential of RNA interference (RNAi) largely depends on the effective delivery of small interfering RNAs (siRNAs) to the target cells. Given the inherent instability of RNA molecules and their inability to penetrate cellular membranes, robust delivery systems are crucial. This section discusses various delivery strategies for RNAi therapeutics, including their advantages and limitations [12].

Lipid-Based Delivery Systems

Since they are biocompatible and promote cellular uptake, lipid-based formulations are one of the most widely used delivery systems for siRNAs and comparison of lipid-based delivery system are shown in Table 3.

Liposomes

- *Description:* Liposomes are spherical vesicles that can contain siRNAs since they are made of phospholipid bilayers.

- *Mechanism:* They facilitate the endocytosis of siRNAs into target cells. Once inside, the siRNAs are released from the liposome, where they can engage with the RISC complex.
- *Advantages:* Non-toxic, versatile in formulation, and effective in delivering siRNAs to various cell types.
- *Limitations:* Circulatory stability is limited, and the mononuclear phagocyte system (MPS) may remove it quickly.

Solid Lipid Nanoparticles (SLNs)

- *Description:* These are nanocarriers made of solid lipids, providing a stable environment for siRNA encapsulation.
- *Mechanism:* SLNs enhance cellular uptake and protect siRNAs from degradation.
- *Advantages:* Controlled release of siRNAs and improved bioavailability.
- *Limitations:* Challenges in scaling up production and possible toxicity [8].

Table 3. Comparison of lipid-based delivery systems.

Delivery System	Advantages	Limitations
Liposomes.	Biocompatible, versatile.	Stability issues, rapid clearance.
Solid lipid nanoparticles.	Controlled release, enhanced bioavailability.	Scaling challenges, potential toxicity.

POLYMER-BASED DELIVERY SYSTEMS

Polymeric carriers are another popular method for siRNA delivery due to their tunable properties and biodegradability and schematic of polymer-based delivery systems are shown in Figure 1.

Cationic Polymers

- *Description:* Cationic polymers can help cells absorb negatively charged siRNAs by forming electrostatic complexes with them.
- Chitosan and polyethylenimine (PEI) are two examples.
- *Advantages:* Enhanced cellular uptake and protection from degradation.
- *Limitations:* Potential cytotoxicity and immunogenicity.

Biodegradable Polymeric Micelles

- *Description:* These are formed by self-assembly of amphiphilic block copolymers and can encapsulate siRNAs.
- *Advantages:* Sustained release of siRNAs and reduced toxicity.
- *Limitations:* Complex formulation and characterization processes.

Figure 4. Schematic of polymer-based delivery systems.

Viral Vectors

Viral vectors have been explored for delivering siRNAs, leveraging their natural ability to infect host cells.

Adenoviral Vectors

- *Description:* These vectors can carry large genetic material and efficiently deliver siRNAs into host cells.
- *Advantages:* High transfection efficiency and the capacity to infect both dividing and non-dividing cells.
- *Limitations:* Risk of immunogenicity and potential toxicity.

Lentiviral Vectors

- *Description:* Long-term expression of siRNAs is made possible by the ability of lentiviral vectors to integrate into the host DNA.
- *Advantages:* Stable and sustained expression.
- *Limitations:* Complexity of production and risk of insertional mutagenesis [8, 11, 13].

Other Delivery Methods

Electroporation

- *Description:* This technique uses electric pulses to create temporary pores in cell membranes, facilitating siRNA entry.
- *Advantages:* High efficiency for transfection, particularly in hard-to-transfect cell types.
- *Limitations:* Requires specialized equipment and may cause cell damage.

Microneedle Patches

- *Description:* These patches can deliver siRNAs transdermally using minimally invasive microneedles.
- *Advantages:* Painless administration and sustained release potential.
- *Limitations:* Limited to specific applications and may require further optimization [14].

APPLICATIONS OF RNAI IN TARGETING VIRAL GENES

RNA interference (RNAi), which selectively silences viral genes, has become a potent weapon in the fight against viral infections. This section explores various applications of RNAi in targeting different viral pathogens, highlighting key studies and results that demonstrate its therapeutic potential [15].

Targeting Human Immunodeficiency Virus (HIV)

HIV is a major global health challenge, and RNAi offers a promising strategy to inhibit its replication.

- *Mechanism:* siRNAs targeting the HIV genome can disrupt the viral life cycle at various stages, including transcription and translation.

Targeting Influenza Virus

The influenza virus poses a significant threat to public health, and RNAi can be utilized to target its various strains.

- *Mechanism:* siRNAs can target the viral RNA polymerase and other essential viral genes, inhibiting replication.

Targeting Hepatitis Viruses

Both Hepatitis B (HBV) and Hepatitis C (HCV) viruses can be targeted using RNAi to silence key genes involved in their life cycles.

Hepatitis B Virus (HBV)

- *Mechanism:* siRNAs can target HBV mRNA, leading to decreased viral protein production and replication.

Hepatitis C Virus (HCV)

- *Mechanism*: Targeting HCV RNA can inhibit its replication and protein synthesis.

Targeting Emerging Zoonotic Viruses

Emerging zoonotic viruses, such as the Zika virus and the Nipah virus have become critical public health concerns.

Zika Virus

- *Mechanism:* siRNAs targeting the Zika virus genome can inhibit viral replication and spread.

Nipah Virus

- *Mechanism:* Targeting the Nipah virus glycoprotein genes can impede viral entry into host cells.

CHALLENGES AND LIMITATIONS

While RNA interference (RNAi) shows great promise as a therapeutic approach for targeting viral genes, several challenges and limitations hinder its widespread application. This section discusses these challenges and potential strategies to overcome them [15].

Delivery Mechanisms

A major obstacle to the therapeutic application of RNA interference is the effective transport of small interfering RNAs (siRNAs) to the intended cells.

Challenges

- *Cell membrane penetration:* siRNAs are negatively charged and large molecules, making it difficult for them to cross lipid membranes without assistance.
- *Degradation:* siRNAs are susceptible to degradation by ribonucleases in biological fluids, reducing their effectiveness before they reach the target cells.

Potential Solutions

- *Nanoparticle carriers:* Utilizing lipid nanoparticles, polymeric nanoparticles, or viral vectors can enhance siRNA delivery and protect them from degradation.
- *Targeting ligands:* siRNAs can be more easily absorbed by conjugating them with ligands that attach to receptors on target cells [16].

Off-Target Effects

Off-target effects occur when siRNAs inadvertently silence non-target genes, leading to unintended consequences.

Challenges

- *Gene silencing:* siRNAs can exhibit partial complementarity to unintended mRNA targets, resulting in the downregulation of essential genes.
- *Toxicity:* Off-target effects can lead to cytotoxicity and adverse physiological responses [9].

Potential Solutions

- *Design optimization:* Utilizing advanced bioinformatics tools to design more specific siRNAs can minimize off-target interactions.
- *Validation methods:* Employing rigorous validation methods to assess off-target effects in preclinical studies can help identify and mitigate these risks [10].

Immune Response

The administration of RNAi-based therapies may elicit an immune response that can limit their effectiveness.

Challenges

- *Activation of immune pathways:* siRNAs can activate the innate immune system, leading to inflammation and reduced therapeutic efficacy.

Potential Solutions

- *Chemical modifications:* Modifying the chemical structure of siRNAs, such as incorporating 2'-O-methyl or 2'-O-ethyl modifications, can reduce immune activation.
- *Delivery modulation:* Utilizing delivery systems that can evade immune detection may improve therapeutic outcomes.

Regulatory Challenges

The regulatory landscape for RNAi therapies is still evolving, presenting challenges for clinical development.

Obstacles

- *Safety and efficacy assessment:* It is essential to establish distinct regulatory pathways for RNAi therapeutics; however, existing recommendations are frequently not modified to accommodate these innovative methods.
- *Approval process:* The availability of RNAi-based medicines may be delayed by the drawn-out and complicated approval process.

Possible Remedies

- *Cooperation:* Early interaction with regulatory bodies can expedite approval and offer insights into the data needs that must be met.
- *Standardized Guidelines:* Development of standardized guidelines for RNAi therapy evaluation can help facilitate regulatory approval [17, 18].

INNOVATIONS AND FUTURE DIRECTIONS

The field of RNA interference (RNAi) has seen significant advancements in recent years, leading to innovative approaches that enhance its therapeutic potential against viral infections. [19]. The most recent developments are examined in this part, along with potential avenues for further study and advancement in RNAi-based treatments.

Advanced Delivery Systems

The development of novel delivery systems is crucial for improving the bioavailability and efficacy of siRNAs.

- *Nanotechnology:* Researchers are exploring nanomaterials, such as gold nanoparticles, silica nanoparticles, and carbon nanotubes for siRNA delivery. Both controlled release and targeted delivery are possible with these materials.
- *Exosome-based delivery:* Exosomes, natural extracellular vesicles, can be engineered to carry siRNAs. They have inherent biocompatibility and can evade the immune system, enhancing the therapeutic potential of RNAi [17].

Optimized siRNA Design

Recent advances in computational biology allow for the design of more effective and specific siRNAs.

- *Machine Learning Algorithms:* Algorithms can predict the most effective siRNA sequences based on target gene characteristics, minimizing off-target effects and enhancing silencing efficiency.
- *Chemically modified siRNAs:* The incorporation of various chemical modifications (e.g., locked nucleic acids, phosphorothioate backbones) can improve stability and reduce immunogenicity [19].

CONCLUSIONS

The development of RNA interference (RNAi) technology has completely changed the field of antiviral medication research and provided a potent treatment approach to fight viral infections. This review highlights the significant progress made in understanding the mechanisms of RNAi and its application in targeting viral genes, demonstrating its potential to enhance therapeutic outcomes.

Summary of Key Findings

1. *Mechanistic insights:* RNAi operates through a well-defined mechanism involving the processing of double-stranded RNA into small interfering RNAs (siRNAs), which then guide the RNA-induced silencing complex (RISC) to complementary viral RNA, leading to its degradation and subsequent inhibition of viral replication.
2. *Therapeutic applications:* Numerous studies have showcased the efficacy of RNAi in targeting various viral pathogens, including HIV, HCV, and influenza. The clinical translation of RNAi-based treatments has a solid basis, thanks to these findings.
3. *Innovative approaches:* Advances in delivery systems, such as nanoparticles and exosome-based vehicles, have significantly improved the bioavailability and effectiveness of siRNAs. Optimized siRNA design using computational algorithms and chemical modifications has further enhanced their therapeutic potential.
4. *Combination therapies:* The integration of RNAi with traditional antiviral drugs and immunomodulatory agents has shown promise in achieving synergistic effects, providing a multifaceted approach to viral treatment.
5. *Regulatory frameworks:* As RNAi therapies move closer to clinical application, the establishment of adaptive licensing models and clear regulatory guidelines will be crucial for ensuring their safe and effective implementation in patient care.

Future Perspectives

RNA interference (RNAi) has a bright future as a treatment approach for viral infections, with several encouraging research and development directions:

- *Expanding target range:* Continued exploration of RNAi against a wider array of viral pathogens, particularly emerging viruses, is essential for addressing global health challenges.
- *Personalized therapeutics:* The application of RNAi in personalized medicine holds the potential to tailor antiviral therapies based on individual patient profiles, enhancing treatment efficacy and minimizing adverse effects.
- *Long-term safety and efficacy studies:* Ongoing research into the long-term effects of RNAi therapies in diverse populations will be necessary to establish their safety profile and ensure broad acceptance in clinical settings.

REFERENCES

1. Agrawal S, Kandimalla ER. Antisense and siRNA as agonists of Toll-like receptors. Natur Biotechgy. 2004 Dec;22(12):1533–7.
2. Campbell TN, Choy FY. RNA interference: past, present and future. Current issues in molecular biology. 2005 Jan;7(1):1–6.

3. World Health Organization. Global hepatitis report 2017. Wrld Hlth Org; 2017.
4. Dyawanapelly S, Ghodke SB, Vishwanathan R, Dandekar P, Jain R. RNA interference-based therapeutics: molecular platforms for infectious diseases. J Biomed Nanotech. 2014 Sep 1;10(9):1998–2037.
5. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. nature. 1998 Feb 19;391(6669):806–11.
6. Tiemann K, Rossi JJ. RNAi-based therapeutics–current status, challenges and prospects. EMBO Molecular Medicine. 2009 Jun 12;1(3):142–51.
7. Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Natr RevGentcs. 2007 Mar;8(3):173–84.
8. Dong Y, Siegwart DJ, Anderson DG. Strategies, design, and chemistry in siRNA delivery systems. Advanced drug delivery reviews. 2019 Apr 1;144:133–47.
9. Ghosal A, Kabir AH, Mandal A. RNA interference and its therapeutic potential. Cntrl Eurpn J Medcn. 2011 Apr;6:137–47.
10. Muthiah M, Park IK, Cho CS. Nanoparticle-mediated delivery of therapeutic genes: focus on miRNA therapeutics. Expert opinion on drug delivery. 2013 Sep 1;10(9):1259–73.
11. Lopez-Fraga M, Wright N, Jimenez A. RNA interference-based therapeutics: new strategies to fight infectious disease. Infectious Disorders-Drug Targets (Formerly Current Drug Targets-Infectious Disorders). 2008 Dec 1;8(4):262–73.
12. Lund E, Dahlberg JE. Substrate selectivity of exportin 5 and Dicer in the biogenesis of microRNAs. InCold Spring Harbor symposia on quantitative biology. Cold Spring Harbor Laboratory Press; 2006 Jan 1;Vol. 71. pp. 59–66.
13. Ambesajir A, Kaushik A, Kaushik JJ, Petros ST. RNA interference: A futuristic tool and its therapeutic applications. Sdi J Biolgcl Sci. 2012 Oct 1;19(4):395–403.
14. Nikam RR, Gore KR. Journey of siRNA: clinical developments and targeted delivery. Nucle Acd Thrputc. 2018 Aug 1;28(4):209–24.
15. Karagiannis TC, El-Osta A. RNA interference and potential therapeutic applications of short interfering RNAs. Cancer Gn Thrpy. 2005 Oct;12(10):787–95.
16. Deng Y, Wang CC, Choy KW, Du Q, Chen J, Wang Q, et al. Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies. Gene. 2014 Apr 1;538(2):217–27.
17. Wang W, Sun L, Huang MT, Quan Y, Jiang T, Miao Z, et al. Regulatory circular RNAs in viral diseases: applications in diagnosis and therapy. RNA biology. 2023 Dec 31;20(1):847–58.
18. Haussecker D. Current issues of RNAi therapeutics delivery and development. J Ctrld Rleas. 2014 Dec 10;195:49–54.
19. Ma Y, Chan CY, He ML. RNA interference and antiviral therapy. Wld J Gastrenterlgy: WJG. 2007 Oct 10;13(39):5169.

